Video

Emerging Agents for R/R CLL

Author(s):

William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Related Videos
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
David C. Fisher, MD
David C. Fisher, MD
Nitin Jain, MD
Kathleen A. Dorritie, MD
Alexey Danilov, MD, PhD
John Seymour, MBBS, FRACP, PhD
A panel of 5 experts on CLL
Related Content
OncLive - stock.adobe.com
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

CLL, Image credit: LASZLO– stock.adobe.com
November 20th 2024

Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Chronic Lymphocytic Leukemia
November 13th 2024

Piecing Together the Proper BTK Usage in CLL

First-Line Zanubrutinib in CLL/SLL
November 13th 2024

First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL